M. Boyce

Single dose methodology to assess the influence of an alpha1-adrenoceptor antagonist on uroflowmetric parameters in patients with benign prostatic hyperplasia.

I. Eardley, B. Gertz, K. Gottesdiener, 2000, British journal of clinical pharmacology.

Assessment in man of SK & F 92657, a novel compound with vasodilator and beta-adrenoceptor blocking activity [proceedings].

M. Boyce, W. L. Burland, A. Bell, 1980, British journal of clinical pharmacology.

Acute Antiemetic Efficacy and Safety of Dolasetron Mesylate, A 5‐HT3 Antagonist, in Cancer Patients Treated with Cisplatin

T. Conroy, G. Prévot, M. Spielmann, 1994, American journal of clinical oncology.

Early clinical trial of MDL 73.147 EF: a new 5-HT3-receptors antagonist for the prevention of chemotherapy-induced nausea and vomiting.

M. Aapro, M. Boyce, P. Alberto, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

Initial Studies in Man to Characterise MDL 73,005EF, a Novel 5-HT1A Receptor Ligand and Putative Anxiolytic

P. Cowen, K. Haegele, M. Boyce, 1991 .